Fabiola Corti
Overview
Explore the profile of Fabiola Corti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Colombo C, Lanfranchi C, Tosetti G, Corti F, Primignani M
Expert Rev Respir Med
. 2024 Jul;
18(5):269-281.
PMID: 38962827
Introduction: Cystic fibrosis (CF)-associated liver disease can significantly affect the quality of life and survival of people with CF. The hepatobiliary manifestations in CF are various, with focal/multilobular biliary cirrhosis...
2.
Colombo C, Ramm G, Lindblad A, Corti F, Porcaro L, Alghisi F, et al.
J Cyst Fibros
. 2023 Feb;
22(2):263-265.
PMID: 36739240
Cystic-fibrosis-related liver disease (CFLD) is a variable phenotype of CF. The severe CFLD variant with cirrhosis or portal hypertension has a poor prognosis and life expectancy. CFTR modulator therapies are...
3.
Zazzeron L, Alicandro G, Dacco V, Lanfranchi C, Bulfamante A, Sciarrabba C, et al.
Dig Liver Dis
. 2022 Oct;
55(3):360-365.
PMID: 36253246
Background: Evidence on the effectiveness of proton pump inhibitors (PPI) as adjuvant therapy to improve maldigestion in people with cystic fibrosis (pwCF) is limited and there is increasing concern on...
4.
Dacco V, Sciarrabba C, Corti F, Rosazza C, Malfitano A, Borzani I, et al.
Pediatr Pulmonol
. 2022 Aug;
57(11):2868-2871.
PMID: 36000266
Lobar atelectasis may be a complication of pulmonary exacerbations in cystic fibrosis (CF). There are no established guidelines on the management of this condition in patients with CF. Therapeutic bronchoscopy...
5.
Colombo C, Alicandro G, Oliver M, Lewindon P, Ramm G, Ooi C, et al.
J Cyst Fibros
. 2021 Apr;
21(2):220-226.
PMID: 33814323
Background: The efficacy and safety of ursodeoxycholic acid (UDCA) for the treatment of liver disease associated with cystic fibrosis (CF) are under discussion, and clinical practice varies among centers. The...
6.
Teri A, Sottotetti S, Biffi A, Girelli D, DAccico M, Arghittu M, et al.
New Microbiol
. 2018 Mar;
41(2):141-144.
PMID: 29498745
Bacteria from the Burkholderia cepacia complex (Bcc) are capable of causing severe infections in patients with cystic fibrosis (CF). Bcc infection is often extremely difficult to treat due to its...
7.
Colombo C, Crosignani A, Alicandro G, Zhang W, Biffi A, Motta V, et al.
J Pediatr
. 2016 Jun;
177:59-65.e1.
PMID: 27297203
Objective: To evaluate the fasting and postprandial serum bile acid composition in patients with cystic fibrosis-associated liver disease (CFLD) after chronic administration of ursodeoxycholic acid (UDCA) (20 mg/kg/day). The aim...
8.
Fraquelli M, Baccarin A, Corti F, Conti C, Russo M, Della Valle S, et al.
Dig Liver Dis
. 2015 Oct;
48(3):271-6.
PMID: 26514737
Background: Ultrasound imaging is used to assess bowel abnormalities in gastrointestinal diseases. We aimed to assess the rate of predefined bowel ultrasound signs and their relationship with gastrointestinal symptoms and...
9.
Terlizzi V, Carnovale V, Castaldo G, Castellani C, Cirilli N, Colombo C, et al.
J Cyst Fibros
. 2015 Jan;
14(4):447-52.
PMID: 25583415
Background: Discordant results were reported on the clinical expression of subjects bearing the D1152H CFTR mutation, and also for the small number of cases reported so far. Methods: A retrospective...
10.
Alicandro G, Bisogno A, Battezzati A, Bianchi M, Corti F, Colombo C
J Cyst Fibros
. 2013 Dec;
13(3):328-34.
PMID: 24291530
Background: In cystic fibrosis (CF), systemic inflammation and pulmonary infections sustain a catabolic response leading to fat free mass (FFM) depletion. Objectives: To investigate the association between recurrent pulmonary exacerbations...